Literature DB >> 23154182

IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells.

Jun Long1, Xulong Zhang, Mingjie Wen, Qingli Kong, Zhe Lv, Yunqing An, Xiao-Qing Wei.   

Abstract

Interleukin (IL)-35 is a novel heterodimeric cytokine in the IL-12 family and is composed of two subunits: Epstein-Barr virus-induced gene 3 (EBI3) and IL-12p35. IL-35 is expressed in T regulatory (Treg) cells and contributes to the immune suppression function of these cells. In contrast, we found that both IL-35 subunits were expressed concurrently in most human cancer cell lines compared to normal cell lines. In addition, we found that TNF-α and IFN-γ stimulation led to increased IL-35 expression in human cancer cells. Furthermore, over-expression of IL-35 in human cancer cells suppressed cell growth in vitro, induced cell cycle arrest at the G1 phase, and mediated robust apoptosis induced by serum starvation, TNF-α, and IFN-γ stimulation through the up-regulation of Fas and concurrent down-regulation of cyclinD1, survivin, and Bcl-2 expression. In conclusion, our results reveal a novel functional role for IL-35 in suppressing cancer activity, inhibiting cancer cell growth, and increasing the apoptosis sensitivity of human cancer cells through the regulation of genes related to the cell cycle and apoptosis. Thus, this research provides new insights into IL-35 function and presents a possible target for the development of novel cancer therapies.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23154182     DOI: 10.1016/j.bbrc.2012.11.004

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

Review 1.  Interleukin-35: Expanding Its Job Profile.

Authors:  Deepali V Sawant; Kristia Hamilton; Dario A A Vignali
Journal:  J Interferon Cytokine Res       Date:  2015-04-28       Impact factor: 2.607

Review 2.  Interleukin-35 in immune-related diseases: protection or destruction.

Authors:  Junfeng Zhang; Yunsheng Zhang; Qingpeng Wang; Chunlei Li; Hongxin Deng; Chuanping Si; Huabao Xiong
Journal:  Immunology       Date:  2019-03-07       Impact factor: 7.397

3.  Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis.

Authors:  Bin Kong; Gan-Bin Liu; Jun-Ai Zhang; Xiao-Xia Fu; Wen-Yu Xiang; Yu-Chi Gao; Yuan-Bin Lu; Xian-Jing Wu; Feng Qiu; Wan-Dang Wang; Lai-Long Yi; Ji-Xin Zhong; Zheng W Chen; Jun-Fa Xu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  Interleukin-35 Limits Anti-Tumor Immunity.

Authors:  Meghan E Turnis; Deepali V Sawant; Andrea L Szymczak-Workman; Lawrence P Andrews; Greg M Delgoffe; Hiroshi Yano; Amy J Beres; Peter Vogel; Creg J Workman; Dario A A Vignali
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

5.  Expression of Epstein-Barr virus-induced gene 3 in cervical cancer: Association with clinicopathological parameters and prognosis.

Authors:  Yan-Mei Hou; Juan Dong; Ming-Yuan Liu; Shan Yu
Journal:  Oncol Lett       Date:  2015-10-30       Impact factor: 2.967

6.  IL-35 expression is increased in laryngeal squamous cell carcinoma and in the peripheral blood of patients.

Authors:  Wei Wu; Hua Jiang; Ying Li; Mao-Xiao Yan
Journal:  Oncol Lett       Date:  2017-03-14       Impact factor: 2.967

7.  Assessing the role of IL-35 in colorectal cancer progression and prognosis.

Authors:  Jin-Cheng Zeng; Zhi Zhang; Tian-Yu Li; Yan-Fang Liang; Hong-Mei Wang; Jing-Jing Bao; Jun-Ai Zhang; Wan-Dang Wang; Wen-Yu Xiang; Bin Kong; Zhi-Yong Wang; Bin-Hua Wu; Xiao-Dong Chen; Long He; Shu Zhang; Cong-Yi Wang; Jun-Fa Xu
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

8.  Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma.

Authors:  Xiangting Qiu; Xinhua Wang; Yucui Song; Lingling Chen
Journal:  Dig Dis Sci       Date:  2016-10-03       Impact factor: 3.199

9.  Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer.

Authors:  Xiaobin Gu; Tian Tian; Bo Zhang; Yang Liu; Chao Yuan; Lijuan Shao; Yajun Guo; Kexing Fan
Journal:  Tumour Biol       Date:  2014-12-06

10.  Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer.

Authors:  Guanghui Chen; Yanfang Liang; Xin Guan; Hui Chen; Qiankun Liu; Bihua Lin; Can Chen; Mingyuan Huang; Jianan Chen; Weiquan Wu; Yi Liang; Keyuan Zhou; Jincheng Zeng
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.